| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.08. | Coiled Therapeutics - First Patient Dosed with new Formulation of AO-252 | - | RNS | ||
| 07.07. | Coiled Therapeutics develops new formulation for AO-252 | 1 | Investing.com | ||
| 07.07. | Coiled Therapeutics - Coiled Advances Next-Generation AO-252 Formulation | - | RNS | ||
| 24.06. | Coiled Therapeutics - Company Presentation | - | RNS | ||
| 24.06. | Coiled Therapeutics - Result of AGM | - | RNS | ||
| 24.06. | Coiled Therapeutics - Appointment of Independent Non-Executive Director | - | RNS | ||
| COILED THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 19.06. | Coiled Therapeutics - Life Sciences Investor Forum | - | RNS | ||
| 18.06. | Coiled Therapeutics - Proactive One2One Investor Forum | - | RNS | ||
| 17.06. | Coiled Therapeutics - Grant of Share Options | 1 | RNS | ||
| 17.06. | Coiled Therapeutics beruft renommierte Onkologen in medizinischen Beirat | - | Investing.com Deutsch | ||
| 17.06. | Coiled Therapeutics establishes medical advisory board | 1 | Investing.com | ||
| 17.06. | Coiled Therapeutics - Establishment of Medical Advisory Board | - | RNS | ||
| 08.06. | Coiled Therapeutics beruft Professor Ozgur Sahin in den wissenschaftlichen Beirat | 3 | Investing.com Deutsch | ||
| 08.06. | Coiled Therapeutics appoints Ozgur Sahin as scientific advisor | 1 | Investing.com | ||
| 08.06. | Coiled Therapeutics - Appointment of Ozgur Sahin as Scientific Advisor | - | RNS | ||
| 29.05. | Coiled Therapeutics - Issue of Equity | - | RNS | ||
| 27.05. | Coiled Therapeutics - Notice of Annual General Meeting | - | RNS | ||
| 19.05. | Coiled Therapeutics shares rise as cross trading begins in New York | 1 | Alliance News | ||
| 19.05. | Coiled Therapeutics startet Handel am US-Markt OTCQB | 1 | Investing.com Deutsch | ||
| 19.05. | Coiled Therapeutics begins trading on US OTCQB market | 2 | Investing.com |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMYLYX PHARMACEUTICALS | 38,660 | 0,00 % | Kaum zu fassen: Die unglaubliche Biotech-Story von Amylyx Pharmaceuticals | Der Biotech-Sektor ist immer wieder für faustdicke Überraschungen gut - sowohl negativ als auch positiv. Bei Amylyx Pharmaceuticals gibt es am Dienstag keine zwei Meinungen: Die Aktie des Biotech-Unternehmens... ► Artikel lesen | |
| MODERNA | 123,92 | -0,26 % | BREAKING: AKTIONÄR-Depotwert Moderna explodiert! | Ein Durchbruch der mRNA-Technologie im Bereich der Onkologie: Moderna und der Entwicklungspartner Merck & Co haben die lang ersehnten ersten Ergebnisse der Phase-3-Studie INTerpath-001 mit Intismeran... ► Artikel lesen | |
| BIONTECH | 99,80 | -0,05 % | Schlafender Biotech-Riese vor der nächsten Wachstumsphase? BioNTech, Emyria und die neue Macht der Datenplattformen | ||
| QIAGEN | 37,565 | -3,02 % | DAX Gewinner am Mittwoch: Qiagen Aktie | Kursentwicklung und Chartanalyse | ||
| BEAM THERAPEUTICS | 29,760 | 0,00 % | Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 375,86 | 0,00 % | Raymond James raises Praxis Precision Medicines price target on pipeline outlook | ||
| APOGEE THERAPEUTICS | 134,73 | -0,01 % | AbbVie schließt Anleiheemission über 8,0 Mrd. US-Dollar zur Finanzierung der Übernahme von Apogee Therapeutics ab | ||
| SUMMIT THERAPEUTICS | 13,150 | 0,00 % | Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)'s Cancer Drug Partnership Create a New Treatment Standard? | ||
| COGENT BIOSCIENCES | 36,710 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,495 | -0,14 % | Recursion, Novavax and Crispr Stocks Trending in Pre-Market-Here's Why | ||
| ENLIVEN THERAPEUTICS | 59,94 | +0,19 % | William Blair startet Coverage für Enliven Therapeutics mit "Outperform" | ||
| MONTE ROSA THERAPEUTICS | 14,300 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 119,91 | +0,09 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 38,150 | 0,00 % | Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile | WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Average Patients Increased 450 to 8,950; Reiterates 2026 WAKIX Net Revenue Guidance of $1.0 Billion... ► Artikel lesen | |
| RELAY THERAPEUTICS | 19,440 | 0,00 % | H.C. Wainwright raises Relay Therapeutics price target to $29 |